Loading...
Genfit S.A.
GNFTF•PNK
Healthcare
Biotechnology
$3.72
$0.00(0.00%)

Over the past four quarters, Genfit S.A. demonstrated steady revenue growth, increasing from $11.48M in Q2 2023 to $61.10M in Q2 2024. Operating income reached $31.22M in Q2 2024, maintaining a consistent 51% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $32.008M, reflecting operational efficiency. Net income rose to $30.31M, with EPS at $0.61. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan